Zolmitriptan — Discount Pricing

Other medications in Pain & Inflammation

• Acetaminophen-Codeine
• Almotriptan
• Baclofen
• Buprenorphine
• Buprenorphine-Naloxone
• Butorphanol
• Caffeine-Ergotamine
• Capsaicin

About Zolmitriptan

If you're one of the millions who experience the debilitating pain of migraine headaches, zolmitriptan may be a medication your doctor prescribes. This powerful treatment helps alleviate acute migraine symptoms, offering much-needed relief. At TheDrugClub, we understand the financial burden of prescription medications and are dedicated to helping our members save significantly on zolmitriptan and many other vital prescriptions.

Zolmitriptan is a medication specifically designed to treat acute migraine headaches in adults, with or without aura. It's important to note that zolmitriptan is not intended to prevent migraines or to treat other types of headaches. For those suffering from the intense throbbing

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Zolmitriptan is approved for (FDA label)

Zolmitriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan tablets if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan tablets treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan tablets are administered to treat any subsequent attacks. Zolmitriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan tablets have not been established for cluster headache.

Source: Read the full FDA label on DailyMed. Label effective date: April 16, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Zolmitriptan (FDA label)

2.5 mg Tablets – Yellow colored, round, biconvex film-coated tablets debossed with 497 on one side and functionally-scored on the other side 5 mg Tablets – Pink colored, round, biconvex film-coated tablets debossed with 498 on one side and plain on the other side Tablets: 2.5 mg functionally-scored ( 3 ) Tablets: 5 mg (not scored) ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: e6628b7a-0b63-4e6f-a5e7-2fa195265235. SPL document ID: 4f68e4d5-c239-eb2d-e063-6294a90af478. Label effective date: April 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Zolmitriptan (FDA label)

The following adverse reactions are described elsewhere in other sections of the prescribing information: Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina [see Warnings and Precautions ( 5.1 ) ]. Arrhythmias [ see Warnings and Precautions ( 5.2 ) ]. Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure [see Warnings and Precautions ( 5.3 ) ]. Cerebrovascular Events [see Warnings and Precautions ( 5.4 ) ]. Other Vasospasm Reactions [see Warnings and Precautions ( 5.5 ) ]. Medication Overuse Headache [see Warnings and Precautions ( 5.6 ) ]. Serotonin Syndrome [see Warnings and Precautions ( 5.7 ) ]. Increase in Blood Pressure [see Warnings and Precautions ( 5.8 ) ]. Most common adverse reactions (≥ 5% and > placebo) were neck/throat/jaw pain/tightness/pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1(888)721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: e6628b7a-0b63-4e6f-a5e7-2fa195265235. SPL document ID: 4f68e4d5-c239-eb2d-e063-6294a90af478. Label effective date: April 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Zolmitriptan (FDA label)

Zolmitriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c oronary artery vasospasm including Prinzmetal’s angina [see Warnings and Precautions ( 5.1 ) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 ) ] History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 ) ] Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 ) ] Ischemic bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug

Source: FDA prescribing information (DailyMed). Set ID: e6628b7a-0b63-4e6f-a5e7-2fa195265235. SPL document ID: 4f68e4d5-c239-eb2d-e063-6294a90af478. Label effective date: April 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Zolmitriptan (FDA label)

Myocardial Ischemia/Infarction, and Prinzmetal Angina : Perform cardiac evaluation in patients with multiple cardiovascular risk factors ( 5.1 ) Arrhythmias : Discontinue zolmitriptan if occurs ( 5.2 ) Chest/Throat/Neck/Jaw Pain, Tightness, and Pressure : Generally not associated with myocardial ischemia; evaluate for CAD in patients at high risk ( 5.3 ) Cerebral Hemorrhage, Subarachnoid Hemorrhage, and Stroke : Discontinue zolmitriptan if occurs ( 5.4 ) Gastrointestinal Ischemic Reactions and Peripheral Vasospastic Reactions : Discontinue zolmitriptan if occurs ( 5.5 ) Medication Overuse Headache : Detoxification may be necessary ( 5.6 ) Serotonin Syndrome : Discontinue zolmitriptan if occurs ( 5.7 , 7.4 ) 5.1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina Zolmitriptan is contraindicated in patients with ischemic or vasospastic coronary artery disease (CAD) . There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of zolmitriptan.

Source: FDA prescribing information (DailyMed). Set ID: e6628b7a-0b63-4e6f-a5e7-2fa195265235. SPL document ID: 4f68e4d5-c239-eb2d-e063-6294a90af478. Label effective date: April 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.